- Home
- AVPT vs APLS Comparison
AVPT vs APLS Comparison
Compare AVPT & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AVPT | APLS |
|---|---|---|
| Founded | 2001 | 2009 |
| Country | United States | United States |
| Employees | 2934 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.7B |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | AVPT | APLS |
|---|---|---|
| Price | $10.48 | $18.51 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 20 |
| Target Price | $16.64 | ★ $31.89 |
| AVG Volume (30 Days) | ★ 1.8M | 1.7M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 112.50 |
| EPS | N/A | ★ 0.20 |
| Revenue | N/A | ★ $1,003,782,000.00 |
| Revenue This Year | $22.66 | N/A |
| Revenue Next Year | $19.11 | $17.97 |
| P/E Ratio | $1,348.94 | ★ $96.85 |
| Revenue Growth | N/A | ★ 28.46 |
| 52 Week Low | $9.86 | $16.10 |
| 52 Week High | $20.25 | $30.48 |
Technical Indicators
Market Signals| Indicator | AVPT | APLS |
|---|---|---|
| Relative Strength Index (RSI) | 41.20 | 26.61 |
| Support Level | $9.86 | $16.89 |
| Resistance Level | $11.42 | $20.42 |
| Average True Range (ATR) | 0.41 | 0.93 |
| MACD | 0.08 | -0.21 |
| Stochastic Oscillator | 38.46 | 0.46 |
Price Performance
Historical ComparisonAbout AVPT AvePoint Inc.
AvePoint Inc provides customizable solutions to optimize SaaS operations, enable secure collaboration, and accelerate digital transformation across technologies and industries. Its Confidence Platform delivers a comprehensive set of cloud-based solutions enabling IT operations, development operations, and cybersecurity professionals to monitor and secure the digital workplace using SaaS tools.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.